Stock Analysis, Dividends, Split History

MDP / Meredith Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price51.60
Volume277,200.00
Market Cap ($M)1,976.14
Enterprise Value ($M)4,815.40
Book Value ($M)1,136.50
Book Value / Share222.47
Price / Book1.79
NCAV ($M)-3,092.10
NCAV / Share-605.27
Price / NCAV-0.65
Share Statistics
Common Shares Outstanding 5,119,163
Common Shares Outstanding3 44,595,052
Common Shares Outstanding2 39,475,889
Scoring Models
Piotroski F-Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.11
Return on Assets (ROA)0.07
Return on Equity (ROE)0.21
Balance Sheet (mrq) ($M)
Assets6,861.30
Liabilities5,206.50
Quick Ratio1.67
Current Ratio1.71
Income Statement (mra) ($M)
Advertising Revenue934,153,000.00
Subscription Revenue321,959,000.00
Circulation Revenues0.00
Other Sales Revenue Net457,249,000.00
Revenues1,713,361,000.00
Disposal Group Including Discontinued Operation Revenue0.00
Operating Income309.12
Net Income188.93
Earnings Per Share Basic4.23
Earnings Per Share Diluted4.16
Cash Flow Statement (mra) ($M)
Cash From Operations219.35
Cash from Investing-117.69
Cash from Financing-117.69
Identifiers and Descriptors
CUSIP589433101
Central Index Key (CIK)65011

Split History

Stock splits are used by Meredith Corp. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

REPH: Recro Pharma Analysis and Research Report

23h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

23h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

Related News Stories

Viant Launches Sales Tactic Optimization and Purchase Cycle Targeting for CPG Marketers

2018-08-15 accesswire
IRVINE, CA / ACCESSWIRE / August 15, 2018 / Viant, a Meredith Corporation people-based advertising technology company, today announced the launch of an enhanced suite of capabilities for CPG marketers through its expanded partnership with IRI, a global leader in innovative solutions and services for consumer, retail and media companies. Viant's new Sales Tactic Optimization solution provides advertisers with weekly insights throughout the campaign, identifying the segments with the most sales activity - enabling marketers to optimize campaigns in-flight. (7-0)

Meredith (MDP) Q4 Earnings Miss, Revenues In Line, Stock Down

2018-08-13 zacks
Meredith Corporation (MDP - Free Report) reported an earnings miss in fourth-quarter fiscal 2018 after four straight quarters of beat. The bottom line declined year over year as well. However, the company’s top line came almost in line with the consensus estimate after a miss in the previous quarter. Following the dismal bottom-line performance, shares of the company have lost 6.7% on Aug 10. In addition, management issued guidance for fiscal 2019, which fell shy of analysts’ expectations. (10-0)

High Yield Dividend Champion Portfolio Update

2018-08-11 seekingalpha
The High Yield Dividend Champion Portfolio is a publicly tracked stock portfolio on Scott's Investments. The goal is to capture quality, high-yield stocks with a history of raising dividends. (7-1)

Index Futures Trade Southward On Persistent Geopolitical Tensions

2018-08-11 zacks
U.S. stock index futures fell sharply lower on Friday as geopolitical conflicts between the United States and Russia as well as with Turkey dented investor’s confidence. Moreover, prolonged trade war fears with China continue to dampen market sentiments. (6-0)

Continued Geopolitical Tensions Drag Futures Down

2018-08-11 zacks
U.S. stock index futures fell sharply lower on Friday as geopolitical conflicts between the United States and Russia as well as with Turkey dented investor’s confidence. Moreover, prolonged trade war fears with China continue to dampen market sentiments. (6-0)

CUSIP: 589433101